INFLIXIMAB COVERAGE ENGINE · PRODUCT + DIAGNOSIS + INSURANCE

How do I get Infliximab
through my insurance?

Infliximab · infliximab (J&J unbranded) · Authorized unbranded reference infliximab · provider-administered IV infliximab

Coverage first → product preference → assistance
Infliximab is one member of the IV infliximab family.

Your insurer may agree that infliximab is medically necessary but require a different infliximab product. MedicineCostHelp treats Remicade, the J&J unbranded product and the major U.S. IV biosimilars as one coverage family.

Important scope: this navigator is for IV provider-administered infliximab. Zymfentra is subcutaneous infliximab-dyyb and typically follows a pharmacy-benefit/self-administered pathway, so it is handled separately.

No account, member ID, name, date of birth or email is needed for this beta. Your selections stay in this page session.

1
WHY IS INFLIXIMAB BEING GIVEN?

Choose the diagnosis / reason.

The same infliximab product family can have very different medical-necessity requirements by diagnosis.

WHY BIOSIMILARS MATTER HERE

“Infliximab is covered” is only half the answer.

Medical necessity

The plan first asks whether the diagnosis meets its infliximab criteria — such as disease severity, prior therapy, specialist involvement, dose/frequency and site of care.

Product preference

Then the plan may require Inflectra, Avsola, Renflexis or another preferred infliximab product before Remicade or a different non-preferred product. That preferred-product layer is often the part patients never see coming.

AFTER COVERAGE

Then solve the patient’s out-of-pocket cost.

The assistance program must match the exact infliximab product that will actually be authorized and infused. That is why MedicineCostHelp puts coverage and biosimilar preference before copay assistance.

J&J withMe — Infliximab →
PLAIN-ENGLISH ANSWERS

What people actually need to know.

How do I get Infliximab through my insurance?

Choose the diagnosis and insurance type above. MedicineCostHelp then connects the request to the insurer’s current infliximab medical policy and, when available, its preferred-product rule. Your individual benefit plan and authorization decision still control.

Can my insurer require a biosimilar or a different infliximab product?

Yes. Many plans publish preferred infliximab products and may require a trial, intolerance, contraindication or other exception before approving a non-preferred product.

Why does the billing code matter?

IV infliximab products use product-specific HCPCS codes such as J1745, Q5103, Q5104 and Q5121. The treatment site must bill the product actually administered and verify current payer/CMS coding.

Is Zymfentra included here?

No. Zymfentra is subcutaneous infliximab-dyyb and generally routes through a pharmacy/self-administered benefit rather than the IV medical-benefit pathway. We keep those paths separate so the coverage answer stays clear.

Important

MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. The member’s benefit plan, medical necessity, prior authorization, product preference, current billing code and site-of-care rules can change the outcome. Product and policy sources in this beta were checked August 20, 2026.

Search another expensive medicine →